Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corp (NQ: SRRK )

9.115 -0.195 (-2.09%)
Streaming Delayed Price Updated: 9:55 AM EDT, Jul 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Scholar Rock Holding Corp

< Previous 1 2 3 4 Next >
New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA
From Scholar Rock
Via Business Wire
Scholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual Meeting
From Scholar Rock
Via Business Wire
Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy
From Scholar Rock
Via Business Wire
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer
From Scholar Rock
Via Business Wire
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
From Scholar Rock
Via Business Wire
Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors
From Scholar Rock
Via Business Wire
Scholar Rock to Participate in the 2022 Wedbush PacGrow Healthcare Conference
From Scholar Rock
Via Business Wire
Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference
From Scholar Rock
Via Business Wire
Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)
From Scholar Rock
Via Business Wire
Scholar Rock Announces $205 Million Registered Direct Offering
From Scholar Rock
Via Business Wire
Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)
From Scholar Rock
Via Business Wire
Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference
From Scholar Rock
Via Business Wire
Scholar Rock to Present at Jefferies Global Healthcare Conference 2022
From Scholar Rock
Via Business Wire
Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities
From Scholar Rock
Via Business Wire
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress
From Scholar Rock
Via Business Wire
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting
From Scholar Rock
Via Business Wire
Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
From Scholar Rock
Via Business Wire
Scholar Rock to Present at Cowen’s 42nd Annual Health Care Conference
From Scholar Rock
Via Business Wire
Scholar Rock to Present Biomarker Strategy for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit
From Scholar Rock
Via Business Wire
Scholar Rock Provides Corporate Update and Highlights Priorities for 2022
From Scholar Rock
Via Business Wire
Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Scholar Rock
Via Business Wire
Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
From Scholar Rock
Via Business Wire
Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B
From Scholar Rock
Via Business Wire
Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
Scholar Rock to Present at Upcoming Healthcare Conferences
From Scholar Rock
Via Business Wire
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology
From Scholar Rock
Via Business Wire
Scholar Rock Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the Child Neurology Society Annual Meeting
From Scholar Rock
Via Business Wire
Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation
From Scholar Rock
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.